Document:

exv10w104

Exhibit 10.104

Select Medical Corporation

4714 Gettysburg Road

Mechanicsburg, PA 17055

December 18, 2008

Mr. S. Frank Fritsch

Select Medical Corporation

4714 Gettysburg Road

Mechanicsburg, PA 17055

RE:      Third Amendment to the Agreement in the Event of a Change of Control of SMC

Dear Mr. Fritsch:

          The following confirms our desire to amend the letter agreement, dated as of March 1, 2000
between you and Select Medical Corporation (the “Company”), a Delaware corporation, as amended on
February 23, 2001 and February 24, 2005 (the “Letter Agreement”) to, among other things, comply
with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended, and the
regulations thereunder.

          In consideration of your past and continued service to the Company and the mutual covenants
and agreements contained in this third amendment to the Letter Agreement (the “Amendment”), the
Company and you hereby agree, intending to be legally bound, as follows:

1. Section 1 of the Letter Agreement is hereby amended and restated in its entirety to read as
follows:

“1. Payment Events.

(a) Post-Change of Control Termination. A “Post-Change of Control Termination”
shall be deemed to occur if (i) within the five-year period immediately following a
Change of Control (as defined below), (A) your employment with the Company is
terminated by the Company without Cause (as defined below) or (B) you terminate
your employment with the Company because (1) there is a reduction, by the Company,
in your compensation from that in effect immediately prior to such Change of
Control or (2) you are required by the Company to relocate your principal place of
employment with the Company to a location anywhere other than the Company’s
principal executive offices in (or within 25 miles of) Mechanicsburg, Pennsylvania
(except for required travel on the Company’s business in a manner that is
substantially consistent with your

 

 

business travel obligations immediately prior to such Change of Control) or (ii) within
the six-month period immediately following a Change of Control, you terminate your
employment with the Company for Good Reason (as defined below).

(b) Pre-Change of Control Termination. A “Pre-Change of Control Termination” shall be
deemed to occur if within the six-month period preceding a Change of Control, your
employment is terminated by the Company other than for Cause, and you reasonably
demonstrate that such termination of employment was at the request of a third party who
has taken steps reasonably calculated to effect such Change of Control.”

2. Section 2 of the Letter Agreement is hereby amended and restated in its entirety to read as
follows:

“2. Payment Amounts.

(a) Post-Change of Control Termination. If a Post-Change of Control Termination occurs,
then (i) the Company agrees that (A) such termination is not a voluntary termination or
a termination “for cause” as contemplated by any of the Company’s or Select Medical
Holdings Corporation’s (“Holdings”) stock option or other incentive plans and any stock
option or other award agreements entered into between you and the Company or Holdings
(including agreements that may be entered into in the future in connection with
additional awards granted pursuant to any of the Company’s or Holdings’ plans) (the
“Award Agreements”) and (B) all unvested, unexercised stock options held by you which
were granted to you by the Company or Holdings and are outstanding immediately prior to
such Post-Change of Control Termination shall become fully vested and exercisable as of
the date of such Post-Change of Control Termination and you will have the right to
exercise, at any time prior to the earlier of three months after the date of such
Post-Change of Control Termination or the expiration date of such options, all such
options to purchase the Company’s or Holdings’ stock notwithstanding any contrary
vesting schedule that may be contained in the applicable plan or Award Agreement and
(ii) the Company shall pay to you, on the first business day of the seventh month
following such Post-Change of Control Termination, in lieu of any other rights to cash
compensation other than the payment of your salary for services performed before the
date of termination and as a severance benefit, a lump-sum cash payment equal to your
total base salary plus bonus compensation from the Company for the preceding three years
(or, if you shall have been employed by the Company for less than three years at the
time of such Post-Change of Control Termination, an amount equal to three times your
average total annual cash compensation for base salary and bonus for your years of
service to the Company).

 

 

(b) Pre-Change of Control Termination. If a Pre-Change of Control Termination
occurs, then the Company shall pay to you, on the first business day of the seventh
month following such Pre-Change of Control Termination, in lieu of any other rights
to cash compensation other than the payment of your salary for services performed
before the date of termination and as a severance benefit, a lump-sum cash payment
equal to your total base salary plus bonus compensation from the Company for the
preceding three years (or, if you shall have been employed by the Company for less
than three years at the time of such termination, an amount equal to three times
your average total annual cash compensation for base salary and bonus for your years
of service to the Company). In addition, in the event that your employment with the
Company is terminated by the Company without Cause (other than pursuant to Section
1(a)) then, notwithstanding any contrary vesting schedule that may be contained in
any of the Company’s or Holdings’ stock option or other incentive plans or any Award
Agreement, all unvested, unexercised stock options held by you immediately prior to
such termination of employment which were granted to you by the Company or Holdings
shall continue to be held by you, but shall cease to further vest except as
specifically provided in this Section 2(b), as follows: if (i) a Change of Control
does not occur during the six-month period immediately following such termination of
employment, or the expiration date of any such options occurs prior to the
occurrence of a Change of Control, such options shall be forfeited with no further
compensation due to you or (ii) a Change of Control occurs during the six-month
period immediately following such termination of employment and you reasonably
demonstrate that such termination of employment was at the request of a third party
who has taken steps reasonably calculated to effect such Change of Control, all such
options that have not otherwise expired shall become vested and fully exercisable
immediately prior to such Change of Control and you shall have the right to exercise
such options at any time prior to the earlier of the date that is three months
following such Change of Control or the expiration date of such options.

3. Section 3(a) of the Letter Agreement is hereby amended and restated in its entirety to read as
follows:

“(a) Change of Control.

     (i) Prior to a Public Offering (as defined below), a Change of Control shall
mean, subject to Section 3(a)(iii) below:

          (1) during any period of twelve consecutive months, any sale, lease, exchange
or other transfer of all or substantially all of the property and assets of the
Company or Holdings (on a consolidated basis) to an entity, other than an entity at
least 75% of the combined voting power of

 

 

the voting securities of which are owned by persons in substantially the same proportion as their
ownership of the Company or Holdings, as applicable, immediately prior to such sale or other
transfer;

          (2) any merger or consolidation to which the Company or Holdings is a party and as a result
of which the holders of the voting securities of the Company or Holdings, as applicable,
immediately prior thereto own less than 50% of the outstanding voting securities of the surviving
entity immediately following such transaction;

          (3) any person’s (excluding WCAS, GTCR and Thoma Cressey Partners, the financial sponsors of
the Company as of the date hereof), including a group’s, becoming the beneficial owner of
securities representing more than 50% of the voting securities of the Company or Holdings then
outstanding.

     (ii) Following a Public Offering, a Change of Control shall mean, subject to Section
3(a)(iii) below:

          (1) any person including a group, but excluding any
stockholder of the Company or Holdings who immediately prior to the
Public Offering beneficially owned 12% or more of the Company’s or
Holdings’ outstanding shares, becomes the beneficial owner of shares of
more than 50% of the total number of votes that may be cast for the
election of directors of the Company or Holdings, as applicable;

          (2) during any period of twelve consecutive months, beginning
immediately after the effective date of the Public Offering, any person
including a group, other than you or any group of which you are a party,
increases their beneficial ownership of voting securities of the Company
or Holdings by a number of voting securities of the Company or Holdings
equal to at least 33% of the total number of votes that may be cast for the
election of directors of the Company or Holdings, as applicable;

          (3) during any period of twelve consecutive months, the
individuals who served on the Board of Directors of the Company as of
the effective date hereof (the “Incumbent Directors”) or who served on the
Board of Directors of Holdings (the “Holdings Board”) as of the effective
date hereof (the “Holdings Incumbent Directors”) cease for any reason to
constitute at least a majority of the Board of Directors of the Company or
the Holdings Board, as applicable; provided, however, that any person
who becomes a director subsequent to the effective date hereof, whose
election or nomination for election was approved by a vote of at least a
majority of the directors then constituting the Incumbent Directors or the
Holdings Incumbent Directors, as applicable, shall for purposes of this

 

 

clause (3) be considered an Incumbent Director or a Holdings Incumbent Director, as applicable;

          (4) the consummation of a merger or consolidation of the Company or Holdings in which the
stockholders of the Company or Holdings, as applicable, immediately prior to such merger or
consolidation, would not, immediately after such merger or consolidation, beneficially own,
directly or indirectly, shares representing in the aggregate at least 50% of the combined voting
power of the voting securities of the corporation issuing cash or securities in the merger or
consolidation (or of its ultimate parent corporation, if any); or

          (5) during any period of twelve consecutive months, the Company or Holdings sells or
otherwise disposes of all or substantially all of such entity’s assets (on a consolidated basis),
other than a sale or disposition by the Company or Holdings of all or substantially all of such
entity’s assets to an entity, at least 50% of the combined voting power of the voting securities
of which are owned by persons in substantially the same proportion as their ownership of the
Company or Holdings, as applicable, immediately prior to such sale or disposition.

     (iii) Notwithstanding the foregoing, in no event shall a “Change of Control” be deemed to
occur for purposes of this Letter Agreement, whether prior to or following a Public Offering,
unless the total consideration for the transaction or transactions which would, absent this clause
(iii), constitute a Change of Control, has a value that is equal to or greater than $3.75 per
share of common stock of the Company or Holdings, as applicable (the “Minimum Value”); provided,
however, that such Minimum Value shall be adjusted to reflect changes to such common stock in the
event of a stock dividend, stock split, reverse stock split, stock combination, reclassification,
recapitalization, or other similar change in the structure or capitalization of the Company or
Holdings, or any other event which in the discretion of the Board of Directors of the Company
necessitates such an adjustment.

     (iv) For purposes of this Section 3(a), (A) the terms “person,” “group,” “beneficial owner,”
and “beneficially own” have the meanings set forth in Section 13(d) of the Securities Exchange Act
of 1934, as amended, and the rules and regulations promulgated thereunder, (B) the term “Public
Offering” shall mean the consummation of the first public offering of shares of common stock of the
Company or Holdings after December 18, 2008 in a firm commitment underwritten offering registered
under the Securities Act of 1933, as amended, on Form S-1 or its successor forms, and (C) the term
“voting securities” shall mean securities, the holders of which are ordinarily, in the absence of
contingencies, entitled to elect the corporate directors (or persons performing similar
functions).”

 

 

4. Section
3(c) of the Letter Agreement is hereby amended and restated in its entirety to read as follows:

“(c) Good Reason. For purposes of this Letter Agreement, you shall have “Good
Reason” to terminate your employment after a Change of Control if (i) you make a
good faith determination that, as a result of such Change of Control, you are
unable to perform your services effectively or there is any significant adverse
change in your authority or responsibilities, as performed immediately prior to
such Change of Control or (ii) the Company’s obligations under this Letter
Agreement are not assumed by the acquiring entity or any of its affiliates in the
event of a Change of Control described in Section 3(a)(5).”

5. A new section 4(c) is added to the Letter Agreement to read as follows:

“(c) Notwithstanding anything contained herein to the contrary, the Gross-Up
Payment must be made no later than the last day of the taxable year following the
taxable year in which you pay the taxes giving rise to such Gross-Up Payment.”

6. The second sentence of Section 5(a) of the Letter Agreement is hereby deleted in its entirety.

7. A new Section 5(g) is hereby added to the Letter Agreement to read as follows:

“(g) Notwithstanding any other provision of this Letter Agreement to the contrary,
if you are a “specified employee” within the meaning of Code Section 409A and the
regulations issued thereunder, and a payment or benefit provided for in this Letter
Agreement would be subject to additional tax under Code Section 409A if such
payment or benefit is paid within six months after your “separation from service”
(within the meaning of Code Section 409A), then such payment or benefit required
under this Agreement shall not be paid (or commence) during the six-month period
immediately following your separation from service except as provided in the
immediately following sentence. In such an event, any payments or benefits that
would otherwise have been made or provided during such six-month period and which
would have incurred such additional tax under Code Section 409A shall instead be
paid to you in a lump-sum cash payment on the earlier of (i) the first regular
payroll date of the seventh month following your separation from service or (ii)
the 10th business day following your death. In addition, if your
termination of employment hereunder does not constitute a “separation from service”
within the meaning of Code Section 409A, then any amounts payable hereunder on
account of a termination of your employment and which are subject to Code Section
409A shall not be paid until you have experienced a “separation from service”
within the meaning of Code Section 409A.”

 

 

8. Except
as amended hereby, the Letter Agreement shall continue in effect in accordance with
its terms.

     Please indicate your acceptance of the above Amendment by signing below in the space
indicated.

	 	 	 	 	 	 	 
	 	 	Very Truly Yours,
	 
	 	 	 	 	 	 
	 	 	SELECT MEDICAL CORPORATION, a
	 	 	Delaware Corporation
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Michael E. Tarvin	 	 
	 

	 	 	 	 

     Michael E. Tarvin,
	 	 
	 

	 	 	 	     Executive Vice President	 	 

	 	 	 	 	 
	 
	 	/s/ S. Frank Fritsch	 	 
	 

	 	 

S. Frank Fritschexv10w1

Exhibit 10.1

JAGOTEC AG

12 June 2009

Cornerstone Therapeutics Inc.

1255 Crescent Green Drive, Suite 250

Cary, NC 27518

USA

Dear Sirs

Manufacturing and Supply Agreement dated 20 August 2007 between Cornerstone Therapeutics Inc.
(“Cornerstone,” formerly known as Critical Therapeutics, Inc.) and Jagotec AG (“Jagotec”) and (for
the purposes of Clause 20 only) SkyePharma PLC (“MSA”)

We write in connection with Clause 9.1 and Schedule 1 of the MSA.

The parties have agreed that:-

	1.	 	The Price for all Product delivered in the Years 2009 (whether before or after the date of
this letter) and 2010 shall be US$[***] per [***] tablets of Product. As a result of the
increase, Jagotec shall issue to Cornerstone a further invoice for any additional amounts due
for Product invoiced prior to the date of this letter and Cornerstone shall pay such
additional amounts within [***] days of receipt of such further invoice;
	 
	2.	 	The Price for Product delivered in the Year 2011 and each Year thereafter shall be increased
as follows:
	 
	 	 	By [***] 2010 and by [***] in each Year thereafter (“Year A”), Jagotec shall notify Cornerstone
of the Price for Product to be delivered in the following Year (“Year B”); provided however,
that the increase in the Price to become effective in Year B shall not be more than [***]% of
the Price of the Product as at [***] in Year A;
	 
	3.	 	The terms of the MSA, and in particular Clause 9.1 and Schedule 1, shall be deemed to be
amended to reflect the matters set out in paragraphs 1 and 2 above;
	 
	4.	 	In all other respects the terms of the MSA shall remain unamended and in full force and
effect;
	 
	5.	 	All capitalized terms used in this letter which are defined in the MSA shall have the same
meaning as is ascribed to such terms in the MSA.

 

			
	[***]	 	Confidential portions of the exhibit have been omitted and filed separately with the
Securities and Exchange Commission.

 

 

We should be grateful if you would sign and return the attached copy of this letter to evidence
your agreement to the above.

Yours faithfully

for and on behalf of:

	 	 	 	 	 	 	 
	JAGOTEC AG

	 	 	 	SKYEPHARMA PLC	 	 
	 
	 	 	 	 	 	 
	By: /s/ Timothy McBride
 

	 	 
	 	By: /s/ Peter Grant
 

	 	 
	Name: Timothy McBride

	 	 	 	Name: Peter Grant	 	 
	Title: Executive Vice President, Commercial

	 	 	 	Title: Chief Financial Officer	 	 

AGREED TO AND ACCEPTED

CORNERSTONE THERAPEUTICS INC.

(Formerly known as Critical Therapeutics, Inc.)

By: /s/ Craig A. Collard

Name: Craig A. Collard

Title: President & Chief Executive Officer

Date: June 12, 2009

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}]]